Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Apr 15, 2021; 13(4): 265-278
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.265
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.265
Table 1 Clinical and pathological characteristics of primary gastric cancer and remnant gastric cancer patients
Primary GC | Remnant GC | ||
Variables | n 284 (%) | n 40 (%) | P value |
Sex | < 0.001a | ||
Female | 118 (41.5) | 5 (12.5) | |
Male | 166 (58.5) | 35 (87.5) | |
Age (yr) | < 0.001a | ||
mean (SD) | 61.6 (12) | 69.0 (7.7) | |
BMI (kg/cm²) | 0.010a | ||
mean (SD) | 24.4 (5.4) | 22.0 (4.1) | |
Albumin (g/dL) | 0.241 | ||
mean (SD) | 4.2 (2.0) | 3.8 (0.6) | |
Hemoglobin (g/dL) | < 0.001a | ||
mean (SD) | 12.3 (2.2) | 10.6 (2.1) | |
Neutrophil lymphocyte ratio | 0.600 | ||
mean (SD) | 2.56 (2.25) | 2.75 (1.20) | |
Charlson-Deyo Comorbidity Index | 0.956 | ||
0-1 | 200 (70.4) | 28 (70) | |
> 1 | 84 (29.6) | 12 (30) | |
ASA classification | 0.136 | ||
I/II | 251 (88.4) | 32 (80) | |
III/IV | 33 (11.6) | 8 (20) | |
Tumor size (cm) | 0.206 | ||
mean (SD) | 4.87 (3.14) | 5.6 (3.3) | |
Lauren’s type | 0.764 | ||
Intestinal | 149 (52.5) | 22 (55) | |
Diffuse/mixed | 135 (47.5) | 18 (45) | |
Grade of histological differentiation | 0.709 | ||
Well/moderately differentiated | 126 (44.4) | 19 (47.5) | |
Poorly differentiated | 158 (55.6) | 21 (52.5) | |
Lymphatic invasion | 0.900 | ||
No | 138 (48.9) | 20 (50) | |
Yes | 144 (51.1) | 20 (50) | |
Venous invasion | 0.292 | ||
No | 188 (66.7) | 30 (75) | |
Yes | 94 (33.3) | 10 (25) | |
Perineural invasion | 0.642 | ||
No | 144 (51.4) | 19 (47.5) | |
Yes | 136 (48.6) | 21 (52.5) | |
Number of lymph nodes | < 0.001a | ||
mean (SD) | 41.9 (17.8) | 23.4 (13.5) | |
pT | 0.590 | ||
T1/T2 | 112 (39.4) | 14 (35) | |
T3/T4 | 172 (60.6) | 26 (65) | |
pN | 0.617 | ||
N0 | 123 (43.3) | 19 (47.5) | |
N+ | 161 (56.7) | 21 (52.5) | |
pTNM | 0.518 | ||
I/II | 155 (54.6) | 24 (60) | |
III/IV | 129 (45.4) | 16 (40) |
Table 2 Expression profiles of primary gastric cancer and remnant gastric cancer patients
Primary GC | Remnant GC | ||
Variables | n 284 (%) | n 40 (%) | P value |
EBV | 0.039a | ||
Negative | 254 (89.4) | 31 (77.5) | |
Positive | 30 (10.6) | 9 (22.5) | |
MSI/MSS status | 0.362 | ||
MSS | 224 (78.9) | 29 (72.5) | |
MSI | 60 (21.1) | 11 (27.5) | |
p53 | 0.121 | ||
Normal | 177 (62.8) | 20 (50) | |
Aberrant | 105 (37.2) | 20 (50) | |
E-cadherin | 0.565 | ||
Normal | 255 90.7) | 35 (87.5) | |
Loss of expression | 26 (9.3) | 5 (12.5) | |
Profiles with altered expression (EBV, MSI, E-cadherin, p53) | < 0.001a | ||
One or none | 261 (91.9) | 26 (65) | |
Two or more | 23 (8.1) | 14 (35) | |
Number of altered profiles | - | ||
0 | 86 (30.3) | 13 (32.5) | |
1 | 175 (61.6) | 13 (32.5) | |
2 | 23 (8.1) | 11 (27.5) | |
3 | 0 (0) | 2 (5) | |
4 | 0 (0) | 1 (2.5) |
- Citation: Ramos MFKP, Pereira MA, Cardili L, de Mello ES, Ribeiro Jr U, Zilberstein B, Cecconello I. Expression profiles of gastric cancer molecular subtypes in remnant tumors. World J Gastrointest Oncol 2021; 13(4): 265-278
- URL: https://www.wjgnet.com/1948-5204/full/v13/i4/265.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i4.265